Cargando…
Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
Despite more than 25 years of research, the molecular targets of quinoline-3-carboxamides have been elusive although these compounds are currently in Phase II and III development for treatment of autoimmune/inflammatory diseases in humans. Using photoaffinity cross-linking of a radioactively labelle...
Autores principales: | Björk, Per, Björk, Anders, Vogl, Thomas, Stenström, Martin, Liberg, David, Olsson, Anders, Roth, Johannes, Ivars, Fredrik, Leanderson, Tomas |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671563/ https://www.ncbi.nlm.nih.gov/pubmed/19402754 http://dx.doi.org/10.1371/journal.pbio.1000097 |
Ejemplares similares
-
S100A9 Interaction with TLR4 Promotes Tumor Growth
por: Källberg, Eva, et al.
Publicado: (2012) -
Vesicular Location and Transport of S100A8 and S100A9 Proteins in Monocytoid Cells
por: Chakraborty, Paramita, et al.
Publicado: (2015) -
Common Interactions between S100A4 and S100A9 Defined by a Novel Chemical Probe
por: Björk, Per, et al.
Publicado: (2013) -
Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors
por: Olsson, Anders, et al.
Publicado: (2010) -
CD14 Is a Co-Receptor for TLR4 in the S100A9-Induced Pro-Inflammatory Response in Monocytes
por: He, Zhifei, et al.
Publicado: (2016)